BillionToOneBLLN +2.04%13 Current Ratio is 10.92 as of Mar. 2026, which is 54% above its 10-year median of 7.10. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, BillionToOne ranks better than 94.86% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BillionToOne's current ratio for the quarter that ended in Mar. 2026 was 10.92.
BillionToOne has a current ratio of 10.92. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BillionToOne's Current Ratio or its related term are showing as below:
BLLN'
s Current Ratio Range Over the Past 10 Years
Min: 1.73 Med: 7.1 Max: 11.69
Current: 10.92
During the past 3 years, BillionToOne's highest Current Ratio was 11.69. The lowest was 1.73. And the median was 7.10.
BLLN's Current Ratio is ranked better than 94.86% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs BLLN: 10.92
BillionToOne (NAS:BLLN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BillionToOne Current Ratio Related Terms
BillionToOne Current Ratio Historical Data
* Premium members only.
The historical data trend for BillionToOne's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Current Ratio distribution charts can be found below:
* The bar in red indicates where BillionToOne's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a Current Ratio of 10.92 as of Mar. 2026. This is 54% above median its historical median of 7.10. Over the past decade, BillionToOne's Current Ratio has ranged from 1.73 to 11.69. According to the industry distribution chart, BillionToOne ranks #11 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 5.1%.
Is BillionToOne's Current Ratio too high?
BillionToOne's current Current Ratio of 10.92 is 54% above median its 10-year median of 7.10. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 11.69. The Medical Diagnostics & Research industry median Current Ratio is 2.06. BillionToOne's value of 10.92 is 430.1% above this industry median. Based on the distribution chart, BillionToOne ranks #11 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Current Ratio compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #11 out of 214 companies for Current Ratio. This places BillionToOne in the top 5% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.06. BillionToOne's value of 10.92 is 430.1% above this benchmark. Historically, BillionToOne's own Current Ratio has ranged from 1.73 to 11.69 over the past decade. While the company's 10-year median is 7.10 vs. the industry median of 2.06, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Current Ratio of 10.92 is 430.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Current Ratio is 10.92, which is 54% above median its own 10-year median of 7.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Current Ratio of 10.92. The current Current Ratio is 10.92, which is 54% above median its 10-year median of 7.10 and 430.1% above the Medical Diagnostics & Research industry median of 2.06. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BillionToOne (BLLN), the current Current Ratio is 10.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 